Director Karin Eastham filed a Form 4 with the SEC on October 28, 2026, disclosing a stock option exercise and a same-day sale of Veracyte, Inc. common stock executed on October 27, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Eastham acquired 10,000 shares of common stock via a stock option exercise at an exercise price of $27.01 per share on October 27, 2026.
  • Shares sold: 14,850 shares were disposed of on October 27, 2026, at a weighted average price of $50.0049, with individual sale prices ranging from $50.00 to $50.05.
  • Post-sale direct holdings: Following both transactions, Eastham directly held 10,247 shares of common stock, according to the filing.
  • Option fully vested: The stock option exercised had an expiration date of June 11, 2029, and was reported as fully vested, with zero derivative securities remaining after exercise.
  • Trading plan: Both transactions were made pursuant to a Rule 10b5-1 plan adopted by Eastham on May 28, 2026.
  • Issuer: Veracyte, Inc. is listed on NASDAQ:VCYT, a company engaged in genomic diagnostics.

Eastham's October 27 Option Exercise and Sale at Veracyte

According to the filing, Karin Eastham, a director of Veracyte, Inc. (NASDAQ:VCYT), exercised a stock option covering 10,000 shares of common stock on October 27, 2026, at an exercise price of $27.01 per share. The filing notes that the option was fully vested and carried an expiration date of June 11, 2029. Following the exercise, the derivative security position was reduced to zero, with no remaining stock options reported.

On the same date, the filing discloses that Eastham disposed of 14,850 shares at a weighted average sale price of $50.0049. The filing notes that individual sales prices ranged from $50.00 to $50.05, and that detailed information on shares sold at each separate price is available to the SEC, the issuer, or a shareholder upon request. After both the option exercise and the share sale were completed, Eastham's direct beneficial ownership of common stock stood at 10,247 shares, as reported in the filing.

The filing states that both transactions were executed under a Rule 10b5-1 plan that Eastham adopted on May 28, 2026. Veracyte is a genomic diagnostics company; the Form 4 was signed by Jonathan Wygant as attorney-in-fact and filed on October 28, 2026. The filing also indicates that the box for transactions made pursuant to a Rule 10b5-1(c) plan was checked.

What Was Disclosed

Veracyte director Karin Eastham reported a stock option exercise of 10,000 shares and a sale of 14,850 shares on October 27, 2026, under a pre-adopted 10b5-1 plan, leaving her with 10,247 directly held shares of common stock.